How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Endometriosis Treatment Market
- By Treatment Type: Hormonal Therapy, Pain Management, Surgical Intervention, Assisted Reproductive Technology (ART), Complementary and Alternative Medicine
- By Drug Class: Gonadotropin-Releasing Hormone (GnRH) Agonists, Progestins, Oral Contraceptives, Aromatase Inhibitors, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- By Surgical Procedure: Laparoscopy, Laparotomy, Hysterectomy, Excision Surgery, Ablation Surgery
- By Patient Age Group: Adolescents (13-19 years), Reproductive Age Women (20-40 years), Perimenopausal Women (41-50 years), Postmenopausal Women (51+ years)
- By Endometriosis Severity: Minimal (Stage I), Mild (Stage II), Moderate (Stage III), Severe (Stage IV)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Hormonal Therapy leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 298 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.182 →
- 12 Company Profiles 14 players: SWOT & benchmarking p.190 →
Full report · locked preview
Everything inside the Endometriosis Treatment Market report
A complete, evidence-based study - 12 chapters and 125 sections covering market size, segmentation across 5 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 5
Drug Class 5
Surgical Procedure 5
Patient Age Group 4
Endometriosis Severity 4
Companies profiled
AbbVie Inc.
Bayer AG
Pfizer Inc.
HRA Pharma (a Novartis company)
Mylan N.V. (now part of Viatris)
Teva Pharmaceutical Industries Ltd.
Endo International plc
Ipsen S.A.
Eli Lilly and Company
Gedeon Richter Plc
Mitsubishi Tanabe Pharma Corporation
Macleods Pharmaceuticals Ltd.
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →AbbVie Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →HRA Pharma (a Novartis company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Mylan N.V. (now part of Viatris)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Teva Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Endo International plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Ipsen S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Eli Lilly and Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Gedeon Richter Plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Mitsubishi Tanabe Pharma Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Macleods Pharmaceuticals Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Sun Pharmaceutical Industries Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Zydus Cadila
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,013M by 2033 · 7.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Hormonal Therapy56.6
- Pain Management8.3
- Surgical Intervention9.1
- Assisted Reproductive Technology (ART)12.1
- Complementary and Alternative Medicine13.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$741.9M → $1,342M · 7.7%
Europe$517.1M → $869.0M · 6.7%
Asia Pacific$472.1M → $822.8M · 7.2%
Latin America$292.3M → $564.4M · 8.6%
Middle East and Africa$224.8M → $389.5M · 7.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.472026
7.482027
7.482028
7.512029
7.512030
7.522031
7.542032
7.552033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- AbbVie Inc.24.6
- Bayer AG9.4
- Pfizer Inc.10.4
- HRA Pharma (a Novartis company)11.8
- Mylan N.V. (now part of Viatris)5.3
- Teva Pharmaceutical Industries Ltd.10.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type14.4%
Drug Class16.7%
Surgical Procedure24.0%
Patient Age Group18.6%
Endometriosis Severity26.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.7
- Europe21.8
- Asia Pacific20.6
- Latin America14.2
- Middle East and Africa9.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | 78 | 93 | 97 | 96 | 80 | 97 | 90 |
| Bayer AG | 78 | 86 | 81 | 78 | 71 | 84 | 80 |
| Pfizer Inc. | 86 | 76 | 65 | 63 | 84 | 65 | 73 |
| HRA Pharma (a Novartis company) | 72 | 73 | 78 | 82 | 68 | 76 | 75 |
| Mylan N.V. (now part of Viatris) | 75 | 52 | 59 | 53 | 60 | 54 | 59 |
| Teva Pharmaceutical Industries Ltd. | 65 | 49 | 52 | 60 | 47 | 64 | 56 |
| Endo International plc | 59 | 41 | 56 | 57 | 65 | 53 | 55 |
| Ipsen S.A. | 41 | 55 | 42 | 44 | 43 | 59 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- AbbVie Inc.
- Bayer AG
- Pfizer Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| AbbVie Inc. | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Bayer AG | ◐ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Pfizer Inc. | ◐ | ✓ | − | − | ✓ | ◐ |
| HRA Pharma (a Novartis company) | − | ◐ | ✓ | ◐ | ◐ | ◐ |
| Mylan N.V. (now part of Viatris) | ◐ | − | − | ◐ | ◐ | ◐ |
| Teva Pharmaceutical Industries Ltd. | ◐ | ◐ | − | ◐ | ◐ | − |
| Endo International plc | − | − | − | ◐ | ✓ | − |
| Ipsen S.A. | − | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1AbbVie Inc.90
2Bayer AG80
3HRA Pharma (a Novartis company)75
4Pfizer Inc.73
5Mylan N.V. (now part of Viatris)59
6Teva Pharmaceutical Industries Ltd.56
7Endo International plc55
8Ipsen S.A.47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
AbbVie Inc.Bayer AG
Challenger2
Strong scale, closing on the leaders.
Pfizer Inc.HRA Pharma (a Novartis company)
Contender1
Focused players with pockets of strength.
Mylan N.V. (now part of Viatris)
Niche3
Specialists in a single segment or region.
Teva Pharmaceutical Industries Ltd.Endo International plcIpsen S.A.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across Endometriosis Treatment Market — a $424M beachhead inside a $6.68B market.
Beachhead (SOM)$424Mobtainable near-term
Serviceable (SAM)$2.46Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Hormonal Therapy
Best fit — highest urgency & budget in Treatment Type.
Economic buyer80 fit
Pain Management
Strong fit — clear ROI and a fast path to value.
End user65 fit
Surgical Intervention
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Class & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Surgical Procedure
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel30%
Digital / self-serve22%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Endometriosis Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified21%
Evaluation11%
Closed-won7%
$20.7KCAC
$101KLTV
4.9:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Endometriosis Treatment Market is a resilient opportunity — $2.75B by 2033, compounding at 4.7%.
TAM · 2025$1.91Btoday
TAM · 2033$2.75Bforecast
CAGR4.7%2027–2033
Cumulative$20.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.75BTotal addressable market
SAM$962MServiceable available market
SOM$172MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.7% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.75BLarge & growingTAM by 2033 at 4.7% CAGR
$962MServiceable nowreachable with today’s model
$172MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.15BBear3.0% CAGR
$2.75BBase4.7% CAGR
$3.52BBull6.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Class optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Endometriosis Treatment Market — a $6.25B market by 2033. Plan: grow share from 10.9% to 16.9%.
Market size · 2033$6.25Btotal addressable
Market CAGR9.5%2027–2033
Target share16.9%from 10.9% today
Revenue ambition$1.06Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.9% | 16.9% | At risk |
| Revenue | $666M | $1.06B | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 32.5% | 45.9% | Ahead |
| Customer retention | 86.0% | 94.4% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Class capability
A defensible second engine — invest in Drug Class to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Class
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $157M capacity & capability investment
- Greenlight bolt-on M&A in Drug Class
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Endometriosis Treatment Market conversation — a $1.71B market you can size, segment and defend in minutes.
Market size · 2033$1.71Btotal opportunity
Growth8.9%CAGR to 2033
Addressable buyers985+accounts in scope
Typical ROI7.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.1×return on cost, year one
< 2 mopayback period
$46K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
AbbVie Inc.Bayer AGPfizer Inc.HRA Pharma (a Novartis company)Mylan N.V. (now part of Viatris)Teva Pharmaceutical Industries Ltd.Endo International plcIpsen S.A.+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Endometriosis Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Endometriosis Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →IVIg Liquid Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportDrugs for Differentiated Thyroid Cancer Market
Market size, share, segmentation and regional forecast.
$598M market · 2025 base year
View reportLyophilized IVIG Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportPorcine Epidemic Diarrhea Vaccines Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportTacrolimus Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportMedical Grade Collagen Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportBovine Blood Products Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportAnimal Blood Products Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportBurn Ointment Market
Market size, share, segmentation and regional forecast.
$635M market · 2025 base year
View reportMetastatic Prostate Cancer Treatment Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportAcidophilus Probiotic Market
Market size, share, segmentation and regional forecast.
$565M market · 2025 base year
View reportCollagen Biomaterial Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.